论文部分内容阅读
目的分析不同质子泵抑制剂三联疗法治疗幽门螺杆菌相关性消化性溃疡的临床疗效。方法将我院160例幽门螺杆菌相关性消化性溃疡患者根据数字随机表法平分成两组。奥美拉唑组用奥美拉唑三联疗法治疗,埃索美拉唑组用埃索美拉唑三联疗法治疗。比较两组治疗疗效。结果埃索美拉唑组治疗疗效高于奥美拉唑组,P<0.05;在副作用方面两组无显著差异,P>0.05;出院时埃索美拉唑组炎性指标优于奥美拉唑组,P<0.05。结论不同质子泵抑制剂三联疗法治疗幽门螺杆菌相关性消化性溃疡的临床疗效均较好,但埃索美拉唑的效果欠佳,安全性高。
Objective To analyze the clinical efficacy of different proton pump inhibitors triple therapy in the treatment of Helicobacter pylori associated peptic ulcer. Methods 160 cases of H. pylori-associated peptic ulcer patients in our hospital were divided into two groups according to the digital random table method. Omeprazole group with omeprazole triple therapy, esomeprazole group with esomeprazole triple therapy. Compare the curative effect of two groups. Results The efficacy of esomeprazole group was higher than that of omeprazole group, P <0.05; there was no significant difference in side effects between the two groups (P> 0.05); the inflammatory index of esomeprazole group was better than that of omeprazole Azole group, P <0.05. Conclusion Different proton pump inhibitors triple therapy for the treatment of Helicobacter pylori-related peptic ulcer clinical efficacy are good, but the effect of esomeprazole poor, high safety.